A drug called tesamorelin helps HIV patients with belly fat buildup lose about 11% of their dangerous internal belly fat in six months, while those on a dummy pill lose almost none.
Scientific Claim
Tesamorelin reduces visceral adipose tissue by 10.9% (21 cm²) in HIV-infected patients on antiretroviral therapy with abdominal fat accumulation after 6 months of treatment compared to placebo (P < 0.0001).
Original Statement
“VAT decreased by −10.9% (−21 cm2) in the tesamorelin group vs. −0.6% (−1 cm2) in the placebo group in the 6-month efficacy phase, P < 0.0001.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The study is a randomized controlled trial with a control group, which allows for causal inference. The verb 'reduces' is appropriate for this design.
Evidence from Studies
Supporting (1)
Unknown Title
In a well-run study, HIV patients on medicine who took tesamorelin lost nearly 11% of their dangerous belly fat in six months, while those on a dummy pill barely lost any — proving the drug works.